Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Cytogenetics are main predictors of outcome in patients with MDS and AML. In fact, a
monosomy 5 (-5) or del5q (excluding typical 5q-syndrome) are mostly poor prognostic markers
also because being frequently part of a complex karyotype. Together, these patients often do
not respond to conventional chemotherapy and can only be cured by allogeneic HSCT.
Nevertheless, even after transplantation the relapse rate is considerably high and in the
majority of patient's relapses occur within the first year after HSCT.
Lenalidomide has been successfully used in MDS patients with del5q, irrespective of
additional cytogenetic abnormalities. Furthermore, in vitro studies have demonstrated also
impressive anti-proliferative effects of the compound in cell lines harbouring a monosomy 5.
Therefore, it seems to be a promising compound in preventing relapse of high-risk MDS or AML
patients with chromosomal abnormalities involving del5q or -5 after allogeneic HSCT. Due to
its immunomodulatory action it might also be able to enhance T - or NK cell mediated graft
versus leukemia effects. Nevertheless, it is unknown whether lenalidomide could modulate or
enhance clinical graft versus host disease.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cumulative incidence of relapse rate
1 year post transplantation
Uwe Platzbecker, PD Dr. med.
Dresden University of Technology, Medizinische Klinik und Poliklinik 1
Germany: Ethics Commission